Table 1 –

Additional frequent tumor alterations in and information about the five WHO 2016 subtypes of adult diffuse glioma.

WHO 2016 classification	Frequent molecular aberrationsa	MGMT promoter methylation (%)b	Median age at diagnosis (years)c	Median overall survival (years)c	Proportion of 2019 diagnoses (%)d
Glioblastoma, IDH-wild type	EGFR amplification CDKN2A or CDKN2B deletion PTEN mutation PDGFRA1 mutation TP53 mutation NF1 mutation Chromosome 7 gain Chromosome 10 loss MDM2 amplification	~40	59	1.2	71
Glioblastoma, IDH-mutant	TP53 mutation Chromosome 10q loss CDKN2A or CDKN2B deletion	~90	38	3.6	7
Astrocytoma, IDH-wild type	PTEN loss EGFR amplification NF1 mutation TP53 mutation PIK3CA mutation	55	52	1.9	5
Astrocytoma, IDH-mutant	TP53 mutation CDKN2A or CDKN2B deletion MYC amplification RTK or RIS mutation	~85	36	9.3	12
Oligodendroglioma, IDH-mutant and 1p19q co-deletion	CIC mutation FUBP1 mutation NOTCH1 mutation PI3K mutation CDKN2A or CDKN2B deletion	~65–100	44	17.5	5

^aData from REFs.^6,8,20,45,46.

^bData from REFs.^45,60–62.

^cData fromREF.³⁷ and in agreement with REFs.^8,11,38,39.

^dData from CBTRUS (2011–2015)²¹ and REFs^27,40.